Thyroid stimulating hormone levels and BRAFV600E mutation contribute to pathophysiology of papillary thyroid carcinoma: Relation to outcomes?

2019 ◽  
Vol 26 (2) ◽  
pp. 129-135 ◽  
Author(s):  
Oksana Sulaieva ◽  
Olena Chernenko ◽  
Yelisaveta Chereshneva ◽  
Dibahan Tsomartova ◽  
Oleksandr Larin
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Stimulating Hormone ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Hormone Levels ◽  
Stimulating Hormone

scholarly journals Thyroid Stimulating Hormone Suppression and Recurrence After Thyroid Lobectomy For Papillary Thyroid Carcinoma

2021 ◽  
Author(s):  
Mi Rye Bae ◽  
Sung Hoon Nam ◽  
Jong-Lyel Roh ◽  
Seung-Ho Choi ◽  
Soon Yuhl Nam ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Stimulating Hormone ◽  
American Thyroid Association ◽  
Regression Analyses ◽  
Papillary Thyroid ◽  
Tsh Suppression ◽  
Thyroid Lobectomy ◽  
Stimulating Hormone

Abstract Background Thyroid lobectomy is recommended as the primary treatment for low-risk thyroid cancer. However, recurrence and hypothyroidism may develop after lobectomy, necessitating thyroid hormone supplementation. The 2015 American Thyroid Association (ATA) guidelines recommended post-lobectomy thyroid-stimulating hormone (TSH) suppression. This study examined the need for TSH suppression and recurrence after lobectomy for unilateral papillary thyroid carcinoma (PTC). Methods This study involved 369 patients who underwent thyroid lobectomy and ipsilateral central neck dissection for PTC between 2007 and 2015. Thyroid function tests were performed before and regularly after lobectomy. Binary logistic regression analyses were used to find factors predictive of the post-lobectomy need for TSH suppression that was defined by the 2015 ATA guidelines. Results Serum TSH concentrations gradually increased after lobectomy: proportions with TSH > 2 mIU/L at post-lobectomy 1, 3 ~ 6, 12, and 24 months were found in 77.0%, 82.3%, 66.7%, and 59.9%, respectively. After lobectomy, 168 (45.5%) patients received levothyroxine (T4) supplementation. Multivariate logistic regression analyses showed that pre-TSH level > 2 mIU/L was the sole independent variable predictive of the need for post-lobectomy TSH suppression (P = 0.003). During the median follow-up of 72 months, recurrence was found in 4 (1.1%) patients who never received T4 supplementation and had post-lobectomy TSH levels > 2 mIU/L. Conclusions Our data show that thyroid lobectomy for unilateral PTC is associated with a low recurrence rate, but a significant risk of hypothyroidism. Preoperative TSH level can predict the need for post-lobectomy TSH suppression compliant with the 2015 ATA guidelines.

Aggressive Papillary Thyroid Carcinoma without Brafv600e Mutation

2014 ◽  
Vol 2 (4) ◽  
Author(s):  
Emine Demirbaş ◽  
Mehmet Aşık ◽  
Semra Özdemir ◽  
Hacer Şen ◽  
Fahri Güneş ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Brafv600e Mutation
Sign in / Sign up

Export Citation Format

Share Document